Jarrett Disbrow insider trades: Aytu Biopharma (AYTU) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jarrett reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 9, 2025 | AYTU | ↑ Buy | 16,666 | $1.50 | $25K | Direct | Jun 10, 2025 (1d) |
| Mar 6, 2018 | AYTU | ↑ Buy | 226,105 | $0.45 | $102K | Direct | Mar 7, 2018 (1d) |
| Nov 2, 2016 | AYTU | ↑ Buy | 166,666 | $1.50 | $250K | Direct | Nov 4, 2016 (2d) |
| May 6, 2016 | AYTU | ↑ Buy | 250,000 | $0.40 | $100K | Direct | May 16, 2016 (10d) |
| Jan 20, 2016 | AYTU | ↑ Buy | 153,846 | $0.65 | $100K | Direct | Jan 21, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jarrett Disbrow's insider trades
Jarrett Disbrow is Chief Business Officer at Aytu Biopharma (AYTU). Since Jan 20, 2016, Jarrett has reported 5 open-market purchases worth $577K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings), shares returned to the company (3 filings), other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AYTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.